NICE has issued draft guidance that does not recommend chlormethine gel for mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL).
List view / Grid view
Filter the results
30 November 2015 | By
The European Medicines Agency (EMA) has accepted for review, the marketing authorisation application (MAA) for Helsinn Group’s anamorelin HCI...
European Commission approves ALOXI injection to prevent nausea and vomiting due to chemotherapy in children as young as one month
27 May 2015 | By Victoria White
Helsinn Group has announced that the European Commission has approved ALOXI injection for the prevention of acute CINV in children aged one to six months...
Helsinn announces that pivotal Phase III trial data for Anamorelin in ROMANA 1 and 2 studies in non-small cell lung cancer patients with anorexia-cachexia will be presented at the 38th European Society for Medical Oncology (ESMO) Congress in 2014
25 September 2014 | By Helsinn
Helsinn Group announces that Phase III data from the largest trial program of its kind to date in anamorelin, a novel, once-daily ghrelin receptor agonist in development for cancer-anorexia-cachexia (CACS) in non-small cell lung cancer will be presented at the 38th European Society for Medical Oncology Congress...
9 December 2010 | By M:Communications
Zealand Pharma, today announces the receipt of a EUR 500,000 milestone payment as part of its license agreement with Helsinn Healthcare...